
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Med.
Sec. Dermatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1544912
The final, formatted version of the article will be published soon.
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cutaneous T-cell lymphoma (CTCL) often presents with early-stage clinical features indistinguishable from atopic dermatitis (AD),posing significant diagnostic challenges. Recent studies have highlighted cases where patients initially diagnosed with AD and treated with biologic agents were subsequently reclassified as having CTCL, though the nature of this relationship remains poorly understood. In this report, we present two cases of mycosis fungoides and one case of Sézary syndrome, all initially diagnosed as AD and treated with biologics, including dupilumab. Furthermore, we conducted a literature review exploring potential associations between AD, biologics, and CTCL. Our objective is to improve clinicians' ability to differentiate between AD and CTCL and provide evidence supporting a possible association between biologic treatments and CTCL. Our findings underscore the need for heightened clinical vigilance and routine use of skin biopsy in refractory eczematous presentations.
Keywords: cutaneous T-cell lymphoma, biologics, atopic dermatitis, Dupilumab, JAK inhibitor
Received: 13 Dec 2024; Accepted: 08 Apr 2025.
Copyright: © 2025 Li, Wang, Zhang, Wang, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yimeng Wang, Peking University Third Hospital, Haidian, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Supplementary Material
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.